Investigators identified that only Trastuzumab+Pertuzumab combination therapy, but not when either antibody used in isolation, allowed for the activation of the classical complement pathway, resulting in both direct complement-dependent cytotoxicity as well as complement-dependent cellular phagocytosis of HER2+ breast cancer cells.
[JCI Insight]
Sorry, but the selected Zotpress account can't be found.
